#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians should be aware that frequent cannabis use may elevate cortisol levels, potentially affecting stress response and hypothalamic-pituitary-adrenal axis function in ways that could complicate management of anxiety, sleep, or mood disorders in their patients. This finding is particularly relevant for patients who use cannabis as self-medication for stress or anxiety, as the drug may paradoxically increase physiological stress markers despite perceived symptom relief. Understanding this disconnect between subjective symptom improvement and objective hormonal changes can help clinicians counsel patients on cannabis use risks and guide more evidence-based treatment decisions.
This study examined cortisol patterns in frequent cannabis users compared to non-users, finding that regular consumption was associated with elevated stress hormone levels rather than the blunted response previously reported in some literature. The findings suggest that chronic cannabis use may dysregulate the hypothalamic-pituitary-adrenal axis, potentially compromising the body’s normal stress response mechanisms. This has direct clinical relevance for patients with anxiety, PTSD, or stress-related disorders who may be using or considering cannabis as a therapeutic agent, as paradoxically elevated cortisol could exacerbate rather than alleviate these conditions. Clinicians should be aware that despite patient perceptions of cannabis as calming or stress-relieving, frequent use may produce counterintuitive neuroendocrine effects that warrant monitoring and discussion during clinical encounters. For patients currently using cannabis to manage stress or anxiety symptoms, this evidence suggests the need for reassessment of treatment efficacy and consideration of alternative therapies with more predictable effects on the stress response system.
“This observational work adds to a mixed literature on how chronic cannabis use affects the hypothalamic-pituitary-adrenal axis, but we’re still parsing correlation from causation and individual variation remains substantial in my clinical experience. The early signals here warrant attention, but I’m cautious about drawing firm conclusions until we have longitudinal, controlled data that accounts for confounding factors like baseline stress, use patterns, and comorbidities.”
🧠 While this study reports elevated cortisol levels in frequent cannabis users, clinicians should interpret these findings cautiously given the cross-sectional design, which cannot establish causation or determine whether baseline stress predisposed individuals to heavier use rather than cannabis causing elevated stress hormones. The discrepancy with prior research on blunted cortisol awakening response highlights methodological variability across cannabis studies, including differences in user populations, dosing patterns, consumption methods, and timing of measurements relative to use. Individual responses to cannabis vary substantially based on strain composition, frequency of use, genetics, and concurrent mental health conditions, making it difficult to generalize population-level findings to individual patients. Clinicians should remain alert to the bidirectional relationship between cannabis use and stress-related physiology when evaluating patients, particularly those with anxiety or mood disorders, while recognizing that some patients may self-medicate with cannabis for stress management. A practical approach
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
